311 related articles for article (PubMed ID: 28657851)
21. Subtraction Images of Gadoxetic Acid-Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma.
Choi SH; Kim SY; Lee SS; Shim JH; Byun JH; Baek S; Lee MG
AJR Am J Roentgenol; 2017 Sep; 209(3):584-591. PubMed ID: 28609188
[TBL] [Abstract][Full Text] [Related]
22. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
[TBL] [Abstract][Full Text] [Related]
23. LI-RADS Version 2018 Targetoid Appearances on Gadoxetic Acid-Enhanced MRI: Interobserver Agreement and Diagnostic Performance for the Differentiation of HCC and Non-HCC Malignancy.
Min JH; Lee MW; Park HS; Lee DH; Park HJ; Lee JE; Park SJ; Kim SS; Park SH; Ha SY; Hwang JA; Cha DI; Park B
AJR Am J Roentgenol; 2022 Sep; 219(3):421-432. PubMed ID: 35319906
[No Abstract] [Full Text] [Related]
24. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of LI-RADS category on MRI in patients with primary hepatic lymphoepithelioma-like carcinoma.
Pan YJ; Liu W; Qiu QX; Miao SL; Zeng MS; Shan Y; Lin J; Xu PJ
Eur Radiol; 2023 Sep; 33(9):5993-6000. PubMed ID: 37014407
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
Jiang H; Song B; Qin Y; Chen J; Xiao D; Ha HI; Liu X; Oloruntoba-Sanders O; Erkanli A; Muir AJ; Bashir MR
Eur Radiol; 2021 Jun; 31(6):3638-3648. PubMed ID: 33245494
[TBL] [Abstract][Full Text] [Related]
27. Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases.
Potretzke TA; Tan BR; Doyle MB; Brunt EM; Heiken JP; Fowler KJ
AJR Am J Roentgenol; 2016 Jul; 207(1):25-31. PubMed ID: 26866746
[TBL] [Abstract][Full Text] [Related]
28. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection.
Shao S; Liang Y; Kuang S; Chen J; Shan Q; Yang H; Zhang Y; Wang B; J Fowler K; Wang J; B Sirlin C
Bosn J Basic Med Sci; 2020 Aug; 20(3):401-410. PubMed ID: 31999940
[TBL] [Abstract][Full Text] [Related]
30. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
Kim SS; Lee S; Kim MJ
Eur Radiol; 2021 May; 31(5):3405-3416. PubMed ID: 33146795
[TBL] [Abstract][Full Text] [Related]
32. Comparison of CT and gadoxetic acid-enhanced MRI with liver imaging reporting and data system to assess liver tumors before resection.
Chen MF; Ho MC; Kao JH; Hwang RM; Deng SB; Yen KC; Liang PC; Wu CH
J Formos Med Assoc; 2024 Mar; 123(3):318-324. PubMed ID: 38044205
[TBL] [Abstract][Full Text] [Related]
33. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma.
Fowler KJ; Potretzke TA; Hope TA; Costa EA; Wilson SR
Abdom Radiol (NY); 2018 Jan; 43(1):149-157. PubMed ID: 28580538
[TBL] [Abstract][Full Text] [Related]
34. MRI Ancillary Features for LI-RADS Category 3 and 4 Observations: Improved Categorization to Indicate the Risk of Hepatic Malignancy.
Kim YY; Choi JY; Kim SU; Lee M; Park MS; Chung YE; Kim MJ
AJR Am J Roentgenol; 2020 Dec; 215(6):1354-1362. PubMed ID: 33052732
[No Abstract] [Full Text] [Related]
35. Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS.
Hwang SH; Park S; Han K; Choi JY; Park YN; Park MS
Abdom Radiol (NY); 2019 Sep; 44(9):3078-3088. PubMed ID: 31165907
[TBL] [Abstract][Full Text] [Related]
36. Contrast-enhanced ultrasound liver imaging reporting and data system v2017: patient outcomes after treatment for early-stage hepatocellular carcinoma nodules with category 3-5 and category M.
Hu YX; Yan CJ; Yun M; Zheng W; Zou XB; Zhang YF; Mao RS; Li LL; Zhou JH
Br J Radiol; 2023 Jul; 96(1147):20220492. PubMed ID: 37066834
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic and MRI features of combined hepatocellular-cholangiocarcinoma in patients with or without cirrhosis.
Yoon J; Hwang JA; Lee S; Lee JE; Ha SY; Park YN
Liver Int; 2021 Jul; 41(7):1641-1651. PubMed ID: 33503328
[TBL] [Abstract][Full Text] [Related]
38. Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria.
Choi SH; Byun JH; Kim SY; Lee SJ; Won HJ; Shin YM; Kim PN
Invest Radiol; 2016 Aug; 51(8):483-90. PubMed ID: 26885632
[TBL] [Abstract][Full Text] [Related]
39. Comparing Survival Outcomes of Patients With LI-RADS-M Hepatocellular Carcinomas and Intrahepatic Cholangiocarcinomas.
Kierans AS; Lafata KJ; Ludwig DR; Burke LMB; Chernyak V; Fowler KJ; Fraum TJ; McGinty KA; McInnes MDF; Mendiratta-Lala M; Cunha GM; Allen BC; Hecht EM; Jaffe TA; Kalisz KR; Ranathunga DS; Wildman-Tobriner B; Cardona DM; Aslam A; Gaur S; Bashir MR
J Magn Reson Imaging; 2023 Jan; 57(1):308-317. PubMed ID: 35512243
[TBL] [Abstract][Full Text] [Related]
40. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
